Martin Mackay

Member of the Board and chairman of the Research & Development Committee

Martin Mackay, Member of the Board and chairman of the Research & Development Committee

 

Mr Mackay co-founded Rallybio LLC, US, in January 2018 and serves in an executive leadership role in the company overseeing all research and non-research functions. Furthermore, Mr Mackay is a senior advisor to New Leaf Venture Partners, LLC, US.

From 2010 to 2013, Mr Mackay was president of Global Research and Development at AstraZeneca plc., UK. Prior to that, Mr Mackay held a number of positions at Pfizer, Inc., US, from 1995 to 2010, including the roles as president and senior vice president within Research and Development. During the period from 1998 to 2014, Mr Mackay was visiting professor at the Department of Pharmacy at King’s College, London, and at the Department of Biomedical Sciences at the University of Lincoln, both in the UK. Prior to that, Mr Mackay served from 1986 to 1995 as head of a number of departments at Ciba-Geigy Pharmaceuticals, UK and Switzerland. From 1983 to 1986, Mr Mackay served as a research fellow at the Department of Molecular Biology at the University of Edinburgh, UK. From 1979 to 1980, Mr Mackay served as a microbiologist at the Chemotherapeutic Research Center at Beecham Pharmaceuticals, UK.

Mr Mackay is member of the board of Charles River Laboratories International, Inc., US.

Mr Mackay has a BSc (First Class Honours) in Microbiology from Heriot-Watt University, Edinburgh, UK, from 1979, and a Doctorate/Ph.D. from University of Edinburgh, UK, from 1984.

Mr Mackay was first elected to the Board of Novo Nordisk A/S in March 2018. His term as a board member expires in March 2019.

In March 2018, the Board of Directors of Novo Nordisk A/S assessed that Mr Mackay is regarded as an independent board member as defined in Section 3.2.1 of the Recommendations on Corporate Governance designated by Nasdaq Copenhagen.

Mr Mackay became chairman of the Research & Development Committee at Novo Nordisk A/S in March 2018.

In January 2018, the Board of Directors assessed that the special competences possessed by Mr Mackay that are important for the performance of his duties are his background as an R&D executive with extensive experience in building a pipeline, acquiring products and managing the portfolio of early-stage and late-stage projects in large international pharmaceutical companies.

Mr Mackay is a male US national, born April 1956.